TY - JOUR
TI - Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
AU - Godman, B.
AU - Hill, A.
AU - Simoens, S.
AU - Selke, G.
AU - Selke Krulichová, I.
AU - Zampirolli Dias, C.
AU - Martin, A.P.
AU - Oortwijn, W.
AU - Timoney, A.
AU - Gustafsson, L.L.
AU - Voncina, L.
AU - Kwon, H.-Y.
AU - Gulbinovic, J.
AU - Gotham, D.
AU - Wale, J.
AU - Cristina Da Silva, W.
AU - Bochenek, T.
AU - Allocati, E.
AU - Kurdi, A.
AU - Ogunleye, O.O.
AU - Meyer, J.C.
AU - Hoxha, I.
AU - Malaj, A.
AU - Hierländer, C.
AU - Sauermann, R.
AU - Hamelinck, W.
AU - Petrova, G.
AU - Laius, O.
AU - Langner, I.
AU - Yfantopoulos, J.
AU - Joppi, R.
AU - Jakupi, A.
AU - Greiciute-Kuprijanov, I.
AU - Vella Bonanno, P.
AU - Piepenbrink, J.
AU - de Valk, V.
AU - Wladysiuk, M.
AU - Marković-Peković, V.
AU - Mardare, I.
AU - Fürst, J.
AU - Tomek, D.
AU - Obach Cortadellas, M.
AU - Zara, C.
AU - Pontes, C.
AU - McTaggart, S.
AU - Laba, T.-L.
AU - Melien, Ø.
AU - Wong-Rieger, D.
AU - Bae, S.
AU - Hill, R.
JO - Expert Review of Pharmacoeconomics and Outcomes Research
PY - 2021
VL - 21
TODO - 4
SP - 527-540
PB - Taylor and Francis Ltd.
SN - 1473-7167, 1744-8379
TODO - 10.1080/14737167.2021.1884546
TODO - article;  cancer model;  Europe;  gene therapy;  health care system;  human;  multicriteria decision analysis;  narrative;  patent;  price;  reimbursement;  uncertainty;  cost;  drug cost;  drug development;  economic model;  economics;  Europe;  health care delivery;  neoplasm, antineoplastic agent, Antineoplastic Agents;  Costs and Cost Analysis;  Delivery of Health Care;  Drug Costs;  Drug Development;  Europe;  Humans;  Models, Economic;  Neoplasms;  Patents as Topic;  Reimbursement Mechanisms
TODO - Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
ER -